Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Phase 1
Terminated
- Conditions
- Hepatocellular CarcinomaRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-08-31
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Apollomics (Australia) Pty. Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT03655613
- Locations
- 🇦🇺
Border Medical Oncology Research Unit, Albury, New South Wales, Australia
🇦🇺Macquarie University, Sydney, New South Wales, Australia
🇦🇺Crown Princess Mary Cancer Centre, Westmead, New South Whales, Australia
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Phase 1
Completed
- Conditions
- Microsatellite InstabilityMismatch Repair DeficiencyCancer of Unknown Primary SiteSolid Tumor
- Interventions
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2022-05-09
- Lead Sponsor
- Apollomics (Australia) Pty. Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03053466
- Locations
- 🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇦🇺Cabrini Health Limited, Malvern, Victoria, Australia
🇦🇺Peter MaCallum Cancer Centre, Melbourne, Victoria, Australia
News
No news found